BFEC
SYRS

Benjamin F. Edwards & Company’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17
Closed -$2K – 1634
2017
Q3 		$2K Buy
+17
New +$3.2K ﹤0.01% 1465

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Benjamin F. Edwards & Company's SYRS Position: Q4 2017 in Review

Benjamin F. Edwards & Company sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2017, closing a stake of 17 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in SYRS in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 69 funds tracked by Wall St. Rank hold SYRS as of Q4 2017.

  • Benjamin F. Edwards & Company reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 17 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $2K.
  • Benjamin F. Edwards & Company first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q3 2017.
  • 69 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2017, filed 17 Jan 2018.